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In Italy, Hib conjugate vaccine was introduced for infants in 1999 and included in the DTaP-HBV-IPV-Hib
combination in 2001, with an uptake of 83.4% in 2002, >90% by 2005, and >95% by 2011. We estimated
the impact of Hib vaccination on hospitalizations for H. influenzae invasive disease in children <5 years.
Age-specific hospitalization rates and hospitalization risk ratios (HRRs) with 95%CI during 2001–2013
were calculated performing time-series analysis. The number of cases reported to the national surveil-
lance of invasive bacterial diseases was compared to the number of hospitalizations between 2007–2013.
Hospitalization rates declined from 2.3 in 2001 to 0.9  100,000 in 2002 (HRR = 0.4, 95%CI = 0.3–0.6,
p < 0.05) among children 1–4 years and from 5.4 in 2001 to 2.4  100,000 in 2005 (HRR = 0.4, 95%
CI = 0.2–0.9, p < 0.05) among infants.
During 2007–2013: 401 cases were reported, 242 were typed, 12.4% were by serotype b; 861 hospital
admissions were recorded. Applying the percentage of typed b strains retrieved from the surveillance to
the number of hospitalizations for invasive H. influenzae disease, an estimated 107 episodes could be
attributable to serotype b.
These findings provided reassuring data on the impact of Hib vaccination on the burden of hospitaliza-
tion for invasive disease in Italian children.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Haemophilus influenzae is an infectious bacterium cause of
meningitis, pneumonia, epiglottitis and other severe infectious dis-
eases (such as septic arthritis, cellulitis, purulent pericarditis, and
bacteremia). Both capsulated (types a, b, c, d, e, or f) and non-
capsulated Haemophilus influenzae can cause invasive disease
primarily among children under five years of age and immunosup-
pressed patients [1,2]. In the absence of vaccination plans, capsu-lated Haemophilus influenzae type b (Hib) has undoubtedly the
highest incidence [3].
The first Hib conjugate vaccines were developed in the late
1980s [4]. Since that time Hib vaccines were widely used in most
industrialized countries and demonstrated high safety and efficacy.
Near elimination of H. influenzae meningitis has been documented
after vaccine introduction [5]. In the USA, where Hib vaccines were
introduced into routine use first, the average annual incidence rate
of invasive Hib disease in children aged <5 years remained below
the Healthy People 2020 (U.S. Department of Health and Human
Services) goal of 0.27  100,000 throughout 2000–2012 and
reached 0.19  100,000 in 2014 [6]. In European countries, in
2012, the notification rate of confirmed cases of invasive
Haemophilus influenzae disease due to all serotypes was 0.49
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between 2008 and 2011) and 0.97  100,000 children under five
years of age. Serotype b infections have remained constantly low
[7].
In Italy, Hib monovalent vaccine was licensed in 1995 [8],
although vaccination was voluntary. It was included in the
National Immunization Program in 1999 with a 2p + 1 schedule
at 3, 5, and 11 months of age [9,10]. Vaccination coverage at age
24 months was estimated at 19.8% for the 1996 birth cohort and
increased to 53.1% for the 1998 birth cohort [11,12]. Since 2001,
the DTaP-HBV-IPV-Hib combined vaccine has being used with an
estimated vaccination coverage that was 83.4% in 2002, more than
90% by 2005, and more than 95% by 2011 [13].
In the first years of vaccine introduction, from 1997 to 2002, an
active laboratory-based surveillance of invasive H. influenzae dis-
ease was implemented in some Italian regions (Piemonte, Liguria,
Toscana, Campania, and Puglia). Later, from 2003 to 2006, cases
of H. influenzae meningitis were collected nationally as a part of a
passive reporting system of bacterial meningitis. Since 2007, data
on cases of H. influenzae invasive disease are routinely reported
to the National Surveillance of Invasive Bacterial Disease (IBD)
[14–16].
Since when Hib vaccination was introduced, the incidence of
confirmed invasive H. influenzae disease in children <5 years
declined from 5  100,000 in 1997 to 0.07  100,000 in 2009;
beginning in 2006, the rate has remained at, or less than,
0.12  100,000, with around half of the cases identified as non-
typeable strains and very few as type b [17,18].
This work aimed at estimating the burden of hospitalization for
invasive H. influenzae disease in children <5 years fifteen years
after vaccine introduction.2. Material and methods
Hospitalization records for invasive H. influenzae disease strati-
fied according to age groups (infants aged <1 year and children
aged 1–4 years) were provided by the Office of National Hospital
Discharge Registry (HDR) for the period 2001–2013 [19]. HDR con-
tains information about each patient discharged from public and
private hospitals and includes data related to both clinical and
organizational aspects of hospitalization. Records include demo-
graphic information, dates of admission and discharge, diagnoses
(one main and up to five secondary diagnoses) and therapeutic
procedures performed during the hospitalization, type of admis-
sion (1-day admission / ordinary admission), and in-hospital mor-
tality. Clinical information is coded using the International
Classification of Diseases, Ninth Revision, Clinical Modification
(ICD9-CM).
An invasive H. influenzae episode was defined as ICD9-CM code
320.0 ‘‘Meningitis due to H. influenzae” or 038.41 ‘‘Septicemia due
to other gram-negative organisms – H. influenzae” or 041.5 ‘‘Bacte-
rial infection in conditions classified elsewhere and of unspecified
site – H. influenzae” if associated with code 320.8 (Other specified
meningitis), 790.7 (Bacteremia), or 038.9 (Unspecified septicemia).
These ICD9-CM codes were scanned across discharge diagnoses in
each child record for any mention of these diseases.
The proportion of 1-day admissions, in-hospital mortality
(number of admissions reporting the code ‘‘Died” / total number
of admissions), the proportion of admissions reporting one or more
comorbidities (ICD9-CM codes for congenital anomalies, immun-
odeficiency, HIV, cardiovascular disease, tumour, etc., as main or
secondary diagnosis), and the proportion of discharge records
reporting an ICD9-CM code for ‘‘Disorders relating to short gesta-
tion and low birthweight” were calculated.Outcome-specific Poisson regression was used for time series
analysis to assess annual hospitalization rates and hospitalization
risk ratios (HRRs), together with 95% confidence interval (95% CI).
Statistical analyses were performed in STATA (version 14; Stata-
Corp, College Station, TX, USA).
Assuming the hospitalization rate for invasive H. influenzae dis-
ease as a proxy of incidence, the time series were evaluated in light
of the vaccination coverage rates achieved in children <24 months
during the examined period [13].
Moreover, in order to assess the size of under-reporting for
invasive H. influenzae disease, cases (all age groups) reported to
the national surveillance of IBD [15,16] during 2007–2013 were
compared to the number of hospitalizations recorded in the same
period, by year and Italian region.
Because hospital discharge records lack serotyping information,
the distribution of H. influenzae serogroups detected by laboratory-
based IBD surveillance was applied to the total number of hospital-
izations in order to estimate the number of cases attributable to
serotype b.
The study protocol was approved by the Institutional Review
Board at the Apulian Regional Observatory for Epidemiology
(PROT:121/OER/2016, March 30, 2016). The study was conducted
according to the principles expressed in the Declaration of Hel-
sinki. Informed consent was not obtained from participants
because both hospitalization and surveillance data were provided
and analysed anonymously.3. Results
Between 2001 and 2013, a total of 183 (62% males) and 140
(56% males) hospitalizations for invasive H. influenzae disease were
recorded among infants aged <1 year and children aged 1–4 years,
respectively. The proportion of 1-day admissions was 5% (9/183)
among infants and 21% (29/140) among children. The in-hospital
mortality rate was 1% (2/183 admission) among infants and 2%
(3/140) among children. Infants hospitalized for invasive H.
influenzae reporting an ICD9-CM code for a chronic condition were
9% (17/183; 12 with congenital anomalies, three with cardiovascu-
lar disease, two with immunodeficiency – HIV not included). The
proportion of children aged 1–4 years with comorbidities was 6%
(8/140; three reporting congenital anomalies, three cardiovascular
disease, one immunodeficiency – HIV not included, one tumour).
The proportion of infants reporting disorders relating to short ges-
tation and low birthweight was 7% (13/183). Over the study period,
a significant decline of hospitalization rates was observed among
children 1–4 years between 2001 and 2002 (from 2.3 to
0.9  100,000; HRR = 0.4, 95% CI = 0.3–0.6, p < 0.05). Similar signif-
icant reduction was seen among infants between 2001 and 2005
(from 5.4 to 2.4  100,000; HRR = 0.4, 95% CI = 0.2–0.9, p < 0.05)
(Fig. 1).
During 2007–2013, 401 cases (all age groups) of invasive H.
influenzae disease due to both encapsulated and non-typeable
strains were reported to the IBD national surveillance. Among
the 242 (60.3%) strains typed, serotype b accounted for 12.4% of
isolates. Lombardia reported the highest number of notifications
(95 cases/9,795,000 inhabitants, according to 2013 census fig-
ures) [15,16], therefore the estimated number of cases that could
be attributable to serotype b was 12. Four regions (Basilicata, Cal-
abria, Puglia, and Umbria, amounting in all to 7,470,000 inhabi-
tants) reported zero cases (Fig. 2). In the same period, a total of
861 hospitalizations for invasive H. influenzae disease were
recorded in the national HDR. Applying the percentage of 12.4%
typed b strains retrieved from the IBD surveillance to the total
number of hospitalizations for invasive H. influenzae, we obtained
an estimated 107 episodes that could be attributable to serotype
Fig. 1. Hospitalization rates for invasive H. influenzae disease in infants <1 year and children 1–4 years, Italy, 2001–2013. Vaccination coverage at age 24 months in the same
period [13].
Fig. 2. Number of hospitalizations and number of cases reported to the National Surveillance of invasive H. influenzae disease, by Italian region, 2007–2013.
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the highest number of discharge records (188/9,795,000 inhabi-
tants), with an estimated 23 cases that could be attributable to ser-
otype b (Fig. 2).4. Discussion
The epidemiological characteristics of Hib disease have mark-
edly changed since the introduction of highly effective Hib conju-
gate vaccine in the countries using it, regardless of their levels of
development and economic status [11,12]. At least 2 doses of Hib
vaccine are required to achieve high effectiveness, up to 98%
(95% CI: 89–100%) against Hib meningitis and to 100% (95% CI:
64–100%) against invasive disease [20].Before the introduction of universal Hib vaccination in Italy, the
incidence of invasive disease caused by H. influenzae type b in chil-
dren aged <5 years increased from 2.5  100,000 in 1994 to
4.5  100,000 in 1998 [8,21], a trend most probably attributable
to the implementation of an active laboratory-based surveillance
of invasive H. influenzae disease in some Italian regions in 1997.
An excellent disease control was achieved following the inclusion
of the Hib vaccine 2 + 1 schedule in the National Immunization
Program in 1999 [18].
Assuming the hospitalization rate for invasive H. influenzae dis-
ease as a proxy of incidence, as the disease is so severe that all
patients are expected to show up in the hospital, a marked decline
was observed between 2001–2013 (Fig. 1), following the imple-
mentation of hexavalent vaccines in Italy. This decline correlated
over time with the vaccine coverage trend for 3 doses of Hib
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achieved more than 95% since 2011 [13]. As a consequence, the
incidence of cases registered during this entire period in Italy
was steadily lower than the incidence reported to The European
Surveillance System (TESSy) for the year 2014 by all 30 EU/EEA
(European Union/European Economic Area) Member States taken
together [22]. A recent study including data on invasive H. influen-
zae disease reported to ECDC during 2007–2014 from 12 EU/EEA
countries (41% of the total EU/EEA population; year of Hib vaccine
introduction ranging from 1992 to 2001; 3-dose vaccination cover-
age >90% during the study period) showed a sustained low notifi-
cation rate for Hib and continued decreasing infection trend in all
age groups. Although this reduction has been greatest among chil-
dren <5 years of age, almost 1 in 5 cases is still caused by Hib, a dis-
ease preventable by vaccination [23].
In 1998, Coen et al. estimated a value of 70% as critical threshold
of vaccination coverage among children <1 year of age required to
eradicate Hib infection [24]. Data from the Veneto region of Italy
suggested that levels below this threshold could substantially
reduce the incidence of Hib invasive disease. In this region, during
1997–1999, a coverage of 26% for primary vaccination in children
1 year of age plus a 31–53% catch-up coverage in children 1–
4 years of age resulted in a 91% reduction of Hib disease in children
<5 years of age [25]. In our study, the hospitalization rates for
invasive H. influenzae disease among infants declined significantly
(-55%) when Hib vaccine coverage achieved more than 90%. Similar
significant reduction (-60%) was observed among children
1–4 years when coverage at 24 months increased from 70.2% to
83.4% (Fig. 1), documenting herd effect in older (unvaccinated)
children.
Moreover, our hospital admissions analysis showed higher rates
of H. influenzae invasive disease (1.6  100,000 infants and
0.2  100,000 children 1–4 years in 2013) than seen in IBD surveil-
lance (0.8  100,000 infants and 0.1  100,000 children 1–4 years
in 2013) [15,16]. Some regions (Lombardia, Emilia Romagna,
Veneto and Friuli-Venezia Giulia) showed a 50% discrepancy in
hospitalization and surveillance reporting (Fig. 2), despite they
are among those regions that are deemed to have more solid regio-
nal surveillance systems and seem less prone to under-reporting or
under-diagnosis compared to other geographical areas [26]. IBD
surveillance data 2016 showed that a group of seven regions (rep-
resenting 43% of the Italian population and including the four
aforementioned) provided 75.7% of all invasive Haemophilus
influenzae disease notifications with an incidence of
0.41  100,000, approximately double than the national one
(0.23  100,000) [16]. These differences suggest that use of data
for only microbiologically confirmed cases might underestimate
incidence of H. influenzae disease, complicating efforts to under-
stand its occurrence and burden, particularly when the evaluation
of vaccination programmes need timely, reliable incidence data.
The pattern of this underreporting is a complex mix of factors,
including availability and use of appropriate diagnostic services,
reporting practices by physicians, and the operation of the surveil-
lance system itself [27]. A possible explanation of the significant
differences in reporting practices between Italian regions could
lie, as seen in other studies, in a lack of feedback on the outcome
of notification activities, perceived by clinicians as no useful action
has been taken, leading to further apathy about the process [28].
Estimates for Italy would suggest that there could be still 12.4%
of subjects admitted to hospital with serotype b disease. This
occurrence has been observed in other countries with effective
Hib vaccination programmes, showing the importance of ongoing
vaccine development and deployment to ensure child health
[29]. In France, where routine Hib vaccination was introduced in
1993, the proportion of type b isolates decreased markedly
between 1991–1992 (80%) and 1995–2007 (16%). During the1999–2007 post-vaccine period, no case of invasive Hib infection
was identified in fully vaccinated children; more than half of the
cases diagnosed in children up to age 15 years occurred in those
not appropriately vaccinated for their age [30]. In Finland, where
universal Hib vaccination was introduced since 1986, serotype b
accounted for 8% of isolates from H. influenzae meningitis cases
reported during 2004–2014 [31].
Some limitations could have affected our analysis. Using data
from hospital discharge database is known to have limitations such
as sensitivity and specificity of the coding, differences in coding
habits over space and mainly time. In this study, the more than
twice higher estimation of H. influenzae disease incidence through
hospital data than seen in IBD surveillance raises the issue of the
specificity of the hospital data (mainly due to lack of serotyping
information) and not only of the poor sensitivity of the IBD surveil-
lance. On the other hand, we could have lost several cases because
a number of the discharge records are coded as meningitis or sep-
ticaemia due to unspecified bacterium, as showed in a recently
published study on meningococcal meningitis burden in Italy [27].
Another limitation is the absence of data on vaccination status
of cases in both national hospital discharge database and IBD
surveillance available data, making our evaluation of the remaining
occurrence of Hib in children fairly weak. Moreover, both hospital-
ization and surveillance data were provided on an anonymous
basis, making the absence of record-verification of vaccination sta-
tus a major study limitation.
In Italy, as in the rest of Europe [22], most invasive H. influenzae
infections are currently caused by non-capsulated H. influenzae
strains [11,18,32,33] and there is still no evidence of serotype
replacement following the introduction of routine Hib vaccination
[22].
Our study, despite its limitations, provided reassuring data on
the sustained success of serotype b vaccination on the burden of
hospitalization due to invasive disease in children in Italy. Main-
taining high vaccination coverage for combined vaccines and
enhancing continuous surveillance are however essential [22].Acknowledgements
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